Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gap Inc (GAP) vs Invesco Ltd. (IVZ) Price & Performance

Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Gap Inc vs Invesco Ltd. — how do they compare? Gap Inc trades at $23.33 (market cap $8.29B), while Invesco Ltd. trades at $30.09 (market cap $13.47B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Gap Inc pays the higher dividend (2.96%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Invesco Ltd. for 77 Days on average.

GAPIVZ
Market Cap
$8.29B$13.47B
Volume
5,470,5644,447,526
Sector
Consumer CyclicalFinancials
52-Week High
$29.13$33.31
52-Week Low
$18.35$22.44
Typical Hold Time
37 Days77 Days
Enterprise Value
$11.53B$23.63B
Dividend Yield
2.96%2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gap Inc

Gap trades at $23.36, down 1.81% for the day, with a bullish technical outlook from moving averages. The company shows strong profitability with a 43.26% gross margin and 8.14% net margin, supported by recent earnings beats. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B. Recent news highlights brand revitalization efforts, including music partnerships and board appointments, signaling strategic moves to engage customers.

The outlook is positive given low valuations (P/E 7.11, P/S 0.58) and analyst consensus target of $25.67, implying upside. Risks include reliance on Old Navy's turnaround and competitive pressures. Institutional activity is mixed, with some funds reducing stakes while others increase positions, reflecting cautious optimism.

Invesco Ltd.

Invesco (IVZ) trades at $30.09, down 0.95% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $281.70 million for 2025 despite revenue growth to $6.38 billion, with a negative net margin of -0.93%. Recent earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Positive developments include strong operating cash flow of $1.53 billion in 2025 and the expansion of its QQQ ETF suite.

The outlook is cautiously optimistic, supported by a consensus price target of $33.71 and no sell ratings among analysts. Key opportunities lie in continued AUM growth and ETF innovation, but risks include profitability challenges and market volatility. The stock's current price near support at $30.00 suggests limited downside if fundamentals improve with upcoming earnings.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GAP
100% Buy0% Sell
Avg holding period · 37 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About Gap Inc

Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.

Read more on GAP →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →